LifeBrite Laboratories, LLC v. Blue Cross Blue Shield of Florida, Inc.

CourtDistrict Court, N.D. Georgia
DecidedJune 17, 2024
Docket1:23-cv-03748
StatusUnknown

This text of LifeBrite Laboratories, LLC v. Blue Cross Blue Shield of Florida, Inc. (LifeBrite Laboratories, LLC v. Blue Cross Blue Shield of Florida, Inc.) is published on Counsel Stack Legal Research, covering District Court, N.D. Georgia primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
LifeBrite Laboratories, LLC v. Blue Cross Blue Shield of Florida, Inc., (N.D. Ga. 2024).

Opinion

UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF GEORGIA ATLANTA DIVISION

LIFEBRITE LABORATORIES, LLC and CHRISTIAN FLETCHER, Plaintiffs, v. CIVIL ACTION NO. BLUE CROSS AND BLUE SHIELD 1:23-cv-03748-JPB OF FLORIDA, INC. d/b/a FLORIDA BLUE; BLUE CROSS BLUE SHIELD HEALTHCARE PLAN OF GEORGIA, INC.; ELEVANCE HEALTH, INC. f/k/a ANTHEM INSURANCE COMPANIES, INC.; UNITEDHEALTH GROUP INCORPORATED; AETNA HEALTH INC. (GEORGIA); AND AETNA HEALTH INC. (FLORIDA), Defendants. ORDER This matter came before the Court on Defendants Blue Cross and Blue Shield of Florida, Inc. d/b/a Florida Blue (“Florida Blue”), UnitedHealth Group Incorporated (“UnitedHealth”), Elevance Health, Inc. (“Elevance”), Blue Cross Blue Shield Healthcare Plan of Georgia, Inc. (“BCBSGA”), Aetna Health Inc. (Georgia) and Aetna Health Inc. (Florida)’s (collectively “Defendants”) Motion to Dismiss (“Motion”) the First Amended Complaint (“FAC”). ECF No. 83. Having reviewed and fully considered the parties’ arguments, the Court finds as follows: I. BACKGROUND As alleged in the FAC, Plaintiff LifeBrite Laboratories, LLC (“LifeBrite”) is

a medical testing laboratory located in Atlanta, Georgia, and Plaintiff Christian Fletcher (“Fletcher”) is the founder and CEO of LifeBrite. LifeBrite and Fletcher are collectively referred to as “Plaintiffs.”

LifeBrite served as a “reference” laboratory for Campbellton Graceville Hospital, Regional General Hospital and Putnam County Memorial Hospital (collectively the “Hospitals”). This means that the Hospitals referred patients to LifeBrite for testing services in connection with the Hospitals’ laboratory

“outreach” programs. An outreach program expands the client base for a hospital’s laboratory services to patients of other entities, such as physician groups, pain management clinics and substance abuse centers. The testing may be done at the

hospital’s laboratory or at an outside “reference” laboratory affiliated with the hospital. Outreach programs improve the financial stability of hospitals by helping them increase revenue and profitability. Under LifeBrite and the Hospitals’ affiliate arrangement, all billing to

patients’ insurance carriers for services LifeBrite rendered was handled by the Hospitals. The Hospitals submitted claims to insurance carriers using the UB-04 uniform medical billing form. One type of billing code that can be designated on the UB-04 billing form is code 141, which signifies that the laboratory services were provided for a “nonpatient” (an individual who is not an “inpatient” or

“outpatient” of the hospital). A claim submitted with a 141 code indicates that the claim concerns services for a patient who was not physically present at the hospital.

Plaintiffs allege that Defendants at some point observed a spike in claims for laboratory testing services submitted by the Hospitals. Defendants had paid millions of dollars for laboratory testing of nonpatients of the Hospitals and were facing the prospect of paying millions more for future claims. Plaintiffs assert that

because Defendants could not find legal support for denying future payments, they embarked on a scheme and conspired to withhold payment of tens of millions of dollars owed to the Hospitals and others involved in the outreach programs.

The scheme allegedly involved Defendants providing false documents and information to the United States Department of Justice (“DOJ”) regarding Plaintiffs and others who were involved in the outreach programs. Specifically, Plaintiffs claim that Defendants reported the laboratory outreach programs and Plaintiffs’ role therein as criminal healthcare billing fraud accomplished through the submission of false claims for payment. Defendants allegedly accused Plaintiffs and others of engaging in a POS (Place of Service) code 22 billing fraud scheme. A POS code 22 is a code used for

the testing of patients physically present at the hospital. To that end, Plaintiffs claim that Defendants falsely inserted a POS code 22 in the documents and spreadsheet data provided to the DOJ, even though Defendants knew that the

invoices submitted by the Hospitals had a billing code of 141 (the code for nonpatients). According to Plaintiffs, the billing code of 141 “honestly and accurately represented” the nature of the transactions. Plaintiffs assert that Defendants also participated in meetings with federal investigators regarding the

alleged scheme. Based on Defendants’ representations, the DOJ obtained a grand jury indictment of Fletcher and others and took the case to trial. Fletcher’s first trial

resulted in a hung jury, and the court denied his motion for acquittal. Fletcher was acquitted at a second trial. The bottom line of Plaintiffs’ FAC is that Defendants are liable for fabricating allegations of billing fraud and then lobbying federal criminal

authorities to bring criminal charges against Plaintiffs with the intent that an indictment would destroy their business and allow the carriers to avoid paying legitimate laboratory testing claims. Plaintiffs allege causes of action for Malicious Prosecution (Count I), Georgia RICO (Count II), Tortious Interference With Contractual Relations (Count

III), Tortious Interference With Business Relations (Count IV), Fraudulent Scheme (Count V) and Defamation (Count VI). Defendants seek to dismiss the FAC on the grounds of lack of subject matter

jurisdiction (pursuant to Federal Rule of Civil Procedure 12(b)(1)) and failure to state a claim (pursuant to Rule 12(b)(6)). Defendants argue this Court lacks subject matter jurisdiction over them because they are immune to Plaintiffs’ claims. This argument will be evaluated under Rule 12(b)(1). See Watkins v.

Willis, No. 22-11602, 2023 WL 4614497, at *4 (11th Cir. July 19, 2023) (affirming the district court’s decision that it lacked subject matter jurisdiction over a defendant who demonstrated that she had sovereign immunity to the claims). All

other arguments for dismissal relate to affirmative defenses or contentions that Plaintiffs have failed to state a claim upon which relief may be granted and will therefore be evaluated under Rule 12(b)(6). II. ANALYSIS The Court begins its analysis with an evaluation of Defendants’ subject matter jurisdiction arguments and will then address the challenge to the sufficiency of Plaintiffs’ pleadings.

A. Subject Matter Jurisdiction Defendants argue that Plaintiffs’ claims are barred by the doctrine of sovereign immunity because Defendants reported their suspicion of fraud to the

federal authorities in the course of their duties administering the federal government’s Federal Employees Health Benefits Program (“FEHBP”). They contend that, in that role, they were acting as agents of and under the authority and direction of the United States Office of Personnel Management (“OPM”), which

has responsibility for the FEHBP. Plaintiffs respond that the immunity does not apply here because Defendants are accused of fraudulent and intentionally tortious conduct; the federal

government is not the real party in interest; and Defendants were not acting under the authority of OPM when they made the subject fraudulent allegations. 1. Legal Standard “[A] motion to dismiss for lack of subject matter jurisdiction pursuant to

Fed. R. Civ. P. 12(b)(1) can be based upon either a facial or factual challenge to the complaint.” McElmurray v. Consol. Gov’t of Augusta-Richmond Cnty., 501 F.3d 1244, 1251 (11th Cir. 2007).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Hemi Group, LLC v. City of New York
559 U.S. 1 (Supreme Court, 2010)
Campbell v. Emory Clinic
166 F.3d 1157 (Eleventh Circuit, 1999)
Bryant v. Avado Brands, Inc.
187 F.3d 1271 (Eleventh Circuit, 1999)
Sweet Pea Marine, Ltd. v. APJ Marine, Inc.
411 F.3d 1242 (Eleventh Circuit, 2005)
Robert Garfield v. NDCHealth Corporation
466 F.3d 1255 (Eleventh Circuit, 2006)
Ambrosia Coal v. Hector Carlos Pages Morales
482 F.3d 1309 (Eleventh Circuit, 2007)
McElmurray v. CONSOLIDATED GOV'T, AUGUSTA-RICHMOND COUNTY
501 F.3d 1244 (Eleventh Circuit, 2007)
Wilchombe v. TeeVee Toons, Inc.
555 F.3d 949 (Eleventh Circuit, 2009)
Yearsley v. W. A. Ross Construction Co.
309 U.S. 18 (Supreme Court, 1940)
Larson v. Domestic and Foreign Commerce Corp.
337 U.S. 682 (Supreme Court, 1949)
Empire Healthchoice Assurance, Inc. v. McVeigh
547 U.S. 677 (Supreme Court, 2006)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Dolcie Lawrence v. Peter Dunbar, United States of America
919 F.2d 1525 (Eleventh Circuit, 1990)
Livingston v. Blue Cross
996 F.2d 314 (Eleventh Circuit, 1993)
United States v. Marvin P. Jones
29 F.3d 1549 (Eleventh Circuit, 1994)
JOhnny Traylor v. Partnership Title Company, LLC
491 F. App'x 988 (Eleventh Circuit, 2012)

Cite This Page — Counsel Stack

Bluebook (online)
LifeBrite Laboratories, LLC v. Blue Cross Blue Shield of Florida, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/lifebrite-laboratories-llc-v-blue-cross-blue-shield-of-florida-inc-gand-2024.